MedPath

Does treatment with repeated doses of albendazole reduce hookworm reinfection rates in an endemic tribal population?

Not Applicable
Registration Number
CTRI/2013/05/003676
Lead Sponsor
Christian Medical College Vellore
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Closed to Recruitment of Participants
Sex
Not specified
Target Recruitment
1350
Inclusion Criteria

1. Permanent resident of the village

2. Willing to stay in the area for the duration of follow-up

3. Willing to have study personnel visit at home

Exclusion Criteria

1. Individuals with syndromic or serological evidence of HIV infection or immunocompromise

2. Individuals who have received albendazole within the last 6 months

3. Pregnant women, individuals with a history of seizure, epilepsy or known neurological disorder

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Reduction in the number of infected people (cure rate, CR)Timepoint: One year post-treatment
Secondary Outcome Measures
NameTimeMethod
Reduction in faecal egg counts (FECR)Timepoint: After each cycle of albendazole, and one year post-treatment
© Copyright 2025. All Rights Reserved by MedPath